Memory updated
Date: June 24, 2024
Glenmark Pharmaceuticals Inc., USA has initiated a voluntary nationwide recall of 114 batches of their Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K. The recall affects both 100-count and 500-count bottles and is due to failed dissolution, which could lead to dangerously high potassium levels (hyperkalemia) and associated risks such as irregular heartbeat and potential cardiac arrest.
The company emphasizes that no reports of hyperkalemia or severe adverse events related to this recall have been received to date. These capsules are commonly used to treat low potassium levels (hypokalemia) and have been distributed nationwide.
Consumers are advised to consult with their healthcare providers before discontinuing use and to report any adverse reactions to the FDA’s MedWatch Adverse Event Reporting program. For return instructions, contact Inmar Rx Solutions at 1-877-883-9273.
This recall underscores the importance of product quality and consumer safety in pharmaceuticals. Stay informed and ensure your health products are safe for use.